Silo Pharma, Inc. · NASDAQ:SILO
Silo Pharma — Investor Presentation (March 2025)
17 slides from Silo Pharma's investor presentation, Mar 10, 2025
Slide 1: Novel Therapeutics for Unmet Medical Needs
NOVEL THERAPEUTICS FOR UNMET MEDICAL NEEDS Investor Presentation March 2025
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS This presentation contains “forward - looking statements” within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estima
Slide 3: Developmental stage biopharmaceutical company addressing unmet medical needs
We are a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions. UNMET MEDICAL NEEDS Post - traumatic stress disorder (PTSD) Stress - induced psychiatric disorders Fibromyalgia and chronic pain disorders Central nervous system (CNS) diseases O
Slide 4: Multiple Levers for Value Creation
Clear timeline to first - in - human clinical trials for lead asset SPC - 15 pending FDA guidance on pre - IND. Exclusive global licenses granted by Columbia University for two portfolio assets. Streamlined 505(b)(2) regulatory pathway for drug approval planned for priority drug candidates.
Slide 5: Under-Addressed Medical Needs
Under - Addressed MEDICAL NEEDS Mental Health SPC - 15 | Intranasal PTSD treatment • Selective intranasal drug compound (non - psychedelic) • Patented nose - to - brain delivery bypasses blood - brain barrier • Direct, heightened drug concentration in the brain • Optimized patient safety and therape
Slide 6: Drug Pipeline
DRUG PIPELINE Our current assets have shown promise in a range of diseases and conditions including PTSD, chronic pain, Alzheimer’s Disease, and multiple sclerosis. Silo Pharma’s Nasdaq: SILO 6
Slide 7: Prophylactic Treatment for PTSD
INTRODUCTION Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate vel
Slide 8: SP-26: Ketamine Implant for Fibromyalgia
Drug: • Subcutaneous time - released ketamine - based injectable dissolvable implant Stage: • Preclinical research Unmet need: • Only FDA - approved drugs for fibromyalgia are 2 antidepressants and 1 anti - seizure medicine 1 • Chronic pain treatment market projected growth to $106.3B in 2028 at 7.9
Slide 9: Neurology: Alzheimer's Disease and Multiple Sclerosis Programs
SPC - 14 : ALZHEIMER’S DISEASE PROGRAMS SPU - 16 : MULTIPLE SCLEROSIS NEUROLOGY Drug: • Novel drug targeting two receptor molecules Stage: • Preclinical research Unmet need: • Treatment market projected growth to $30.8B in 2033, at 18.8% CAGR 1 Competitive advantages: • Has shown efficacy against lu
Slide 10: Timeline
JANUARY Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. APRIL FEBRUARY Lorem ipsum dolor sit amet, consectetur adipi
Slide 11: Creating Value
VALUE Our strategic business platform supports our ongoing development of novel drugs with the potential to transform patient care. Creating Nasdaq: SILO 11
Slide 12: FDA's 505(b)(2) Abbreviated Regulatory Pathway
FDA’s 505(b)(2) ABBREVIATED REGULATORY PATHWAY Silo Pharma intends to utilize the FDA’s streamlined 505(b)(2) pathway for its top two priority drug candidates, SPC - 15 and SP - 26. Section 505(b)(2) of the Federal Food, Drug, and Cosmetics Act (FDCA) • Streamlined pathway to New Drug Application (N
Slide 13: Management and Key Personnel
Eric Weisblum CEO ◉ 20+ years investing, building and managing businesses ◉ Prior president of Sableridge Capital ◉ Former board member of Aikido Pharma, a Nasdaq - listed biotech company focused on the commercialization of oncology therapeutics James Kuo, M.D., MBA Vice President of R&D ◉ Current m
Slide 14: Directors
Wayne Linsley Director ◉ 40 years in business management ◉ Wide and varied skillset including sales and sales management, finance (public and private companies), accounting, audit support and financial reporting ◉ Independent director for Hoth Therapeutics Inc. (NASDAQ: HOTH) and DatChat Inc. (NASDA
Slide 15: Key Collaborations and Intellectual Property
Key Collaborations and Exclusive collaborations with prominent medical research partners provide valuable IP, assets, and time - to - market advantages. INTELLECTUAL PROPERTY Columbia University • Exclusive worldwide rights to develop, manufacture, and commercialize SPC - 15 and SPC - 14 • Extensive
Slide 16: Creating Value
Pathway to first - in - human trials SPC - 15 SP - 26 502(b)(2) Exclusivity Non - opioid pain relief Streamlined pathway to FDA approval Strong asset protection Large CNS markets Market Size Partners Credentials Capital Prominent collaborations Broad life sciences expertise Sufficient resources, no
Slide 17: Thank you
Nasdaq: SILO Thank you. Silo Pharma, Inc. | 677 N. Washington Blvd., Sarasota, FL 34236 Investor Relations Contact: 800 - 705 - 0120 | investors@silopharma.com 17